

In Vitro Anti-inflammatory Activity of Quinoxalin Sulfonamides

Lata C. Potey^{1*}, Rajendra Marathe², Prafulla Sable³

¹Hi-Tech College of Pharmacy, Chandrapur, Maharashtra, India

²Government College of Pharmacy, Aurangabad, Maharashtra, India

³University Department of Pharmaceutical Sciences, Nagpur University, Nagpur, Maharashtra, India

Abstract : Quinoxaline is six membered heterocyclic nitrogen containing two nitrogen atoms are based on pyrazine so also called as benzopyrazine. α dicarbonyl compounds reacts with aromatic ortho-diamine by consecutive addition-elimination mechanism to give quinoxalines.¹Quinoxaline have become attractive target of extensive research due to its inherent properties and therapeutic uses. Quinoxaline finds many pharmacological activities like antibacterial, antifungal, antitubercular, anti-inflammatory, antihyperglycemic, antitumor etc.

The present study includes the synthesis of sulfonamide derivatives of quinoxalines, by addition-elimination mechanism. All derivatives were characterized by TLC, IR, and MS1HNMR. Quinoxaline sulfonamide derivatives were then subjected to anti-inflammatory screening on albino rat by carageenan induced paw edema and activity was recorded by Plethysmometer (UGO Basile 7140).

Key words : Quinoxaline; Anti-inflammatory; paw edema.

1. Introduction:

Quinoxaline is also called as benzopyrazine. It is heterocyclic compound containing benzene ring & pyrazine ring. Pyrazine are stable, colorless compound which are soluble in water. Unlike pyridine, they are expensive & not readily available & so are seldom used as starting material for synthesis of their derivative. Diazines are fused to benzene ring to form quinoxaline. The pyrazine ring system is found in the fungal metabolite aspergillic acid and in dihydro form in luciferin of several beetles including the fire fly is responsible for the chemiluminescence of this ostracod. Methoxypyrazine are very important component of aroma of many fruit's and vegetable such as Peas and Capsicum peppers and also of wines.




Figure 1: Synthesis of 2,3-diphenylquinoxaline 7-sulfonylchloride (parent compound).

1.1 Naturally Occurring Pyrazine & Quinoxaline

Cyridina Luciferin Aspergillilic acid Methoxy Pyrazine (food aroma)




Figure 2: Scheme for synthesis 7-sulfonamide derivatives of 2, 3-diphenylquinoxaline

1.3 Biological Activities of Quinoxaline

1.3.1 Antimalarial against Plasmodium falciparum.

Malaria is by far the world's most important tropical parasitic disease. Mortality, currently estimated at over a million people per year has risen in recent years, probably due to increasing resistance to antimalarial medicines.

E. Vicente *et al.* Synthesized new active compound from lead compound 3- (4'-chlorophenyl) quinoxaline -2- carbonitrile 1,4- di-N-oxide, which was subjected to a structural change in order to obtain new active compounds : replacement of benzene in position 3 of the quinoxaline subunit by a heteroaromatic 5-member ring, 2-furane or 2-thiene. All the synthesized compounds were evaluated for antimalarial activity against Plasmodium falciparum. The 3-(2'-furyl) quinoxaline -2- carbonitrile 1,4-di-N-oxide derivatives appear to be a novel and promising antimalarial candidates.[2]

1.3.2 Anti-inflammatory and antioxidant

Many non-steroidal anti-inflammatory drugs have been reported to act as inhibitors of free radical production or as radical scavenger's compounds with antioxidant properties could be expected to offer protection in rheumatoid arthritis and inflammation and to lead to potentially effective drugs. Thus, Asuncion Burguete *et al.* , synthesized novel ring substituted 3-phenyl -1- (1,4-di-N-oxide quinoxaline-2-yl) -2-propen-1-one derivatives and of their 4,5-dihydro-(1H)-pyrazole analogues. Synthesized compounds were evaluated for anti-inflammatory and antioxidant activity. The tested compounds inhibit the carrageenan-induced rat paw edema (4.5-56.1%) and present important scavenging activities. [3]

1.3.3 Anti- HIV

Since the human immunodeficiency 1 (HIV-1) was first confirmed as the causative agent of acquired immunodeficiency syndrome (AIDS). These are many clinical drugs, non-nucleoside reverse transcriptase inhibitors, which interact with a specific allosteric non-substrate binding site on HIV-1 reverse transcriptase, have proved to be effective anti-HIV drugs because of their high potency, low toxicities, and improved pharmacokinetics. Thus, Bailing Xu- *et al*, synthesized N⁴ - (hetero) arylsulfonylquinoxalinones and their analogs and tested for anti viral activity as HIV-1 reverse transcriptase inhibitors.[4]

The anti-HIV-1 activities of all target compounds were evaluated by a cell-based HIV-1 replication pharmacological model which was set up by HIV-1 (pNL4-3) core packed with vesicular stomatitis virus glycoprotein. The level of HIV-1 replication was presented by a reporter gene expression (i.e., luciferase activity) in infected cells.

1.3.4 Anti cancer


Sandra piras, *et.al.* , synthesized Methyl [4-(substituted 2-quinoxalinyloxy) phenyl] acetates and ethyl N-[[4-(substituted 2-quinoxalinyloxy) phenyl] acetyl] glutamate analogs of methotrexate and evaluated for in vitro anti cancer activity bioisosteric replacement of pteridine ring with 6 (7) – trifluoromethyl quinoxaline affords a good substrate for the classical antifolate analogs, and bioisosteric replacement of 2- NH group with an oxygen that in some cases was of relevance in anticancer activity. Quinoxalines bearing a 2 - (4 – substituted phenoxy) substituent were endowed with potent antitumor activity.[5]

2. Material and Method

2.1 Synthesis of 2, 3-diphenylquinoxaline 7-sulfonylchloride

0.01 moles of 2, 3 diphenylquinoxaline (2.84g) was treated with chlorosulfonic acid under ice-cold condition in fuming cupboard with constant stirring. The stirring was continued until the reaction reaches worm temperature. The resultant mixture was poured into water to give sulfonylchloride derivative shown in fig. 1. [1]

2.1.1 Scheme



2.2 General procedure for the synthesis of Quinoxaline Sulfonamides

Sulfonylchloride quinoxaline derivative was reacted with various primary and secondary amines as per given condition. Then reaction mixture was cooled and poured into water to get sulfonamide derivative of 2,3-diphenylquinoxaline. The crude product was recrystallized from 90% ethanol, and reaction was monitored by TLC, as per given in Fig 2 and Table 1. [1]

2.2.1 Scheme




Table 1: Different derivatives prepared by above scheme

Sr. No.	Name of derivative	R	R'
L1	2,3-Diphenyl ,7-sulfonamido quinoxaline	H	-
L2	2,3-Diphenyl,7-(N phenyl)-sulfonamidoquinoxaline	C ₆ H ₅	-
L3	2,3-Diphenyl ,7-(2,nitro,N-phenyl)-sulfonamido quinoxaline	C ₆ H ₅ -NO ₂	-

RNHR'


N-Disubstituted sulfonamide

3. Result and Discussion

3.1 Identification & characterization

The identification & characterization of prepared compound were carried out on the basis of physical, chemical, and spectral data given in Table 2,3,4,5 such as

1. Melting point. (MP)
2. Thin layer chromatography. (TLC)
3. Infrared Spectroscopy. (IR)
4. Mass Spectrometry.(MS)




Melting point 194⁰c, molecular formula C₁₂H₁₅N₃O₂S, Rf Value 0.39, molecular weight 377

IR data:

Table 2 : Observed group frequencies in IR spectrum of 2, 3-Diphenyl, 7-(N phenyl) sulfonamidoquinoxaline

Functional Group	Frequency (cm ⁻¹)
C=N	1673.98 (1690-1630)
C=C (Aromatic stretch)	1583.62 (1475-1600)
CH aromatic	3087.02 (3100-3000)
S=O	1172.56(1180-1140) 1383.77 (1370-1300)
Pri. NH ₂	3423.35(3500-3300)

L2:




Melting point 95⁰c, molecular formula C₂₆H₁₉O₂N₃S, Rf Value 0.42, molecular weight 466

IR data:

Table 3: Observed group frequencies in IR spectrum of 2, 3-Diphenyl, 7-(N phenyl)-sulfonamidoquinoxaline

Functional Group	Frequency (cm ⁻¹)
C=C (Aromatic stretch)	1496.20 (1475-1600)
S=O	1156.16(1180-1140) 1347.21 (1370-1300)
NH ₂	3055.60 (3500-3300)
Mono sub. benzene	770.40 (790-770)

L3:



Melting point 70⁰c, molecular formula C₂₆H₁₉O₄N₄S, Rf Value 1.2, molecular weight 483

Table 4: Observed group frequencies in IR spectrum of 2, 3-Diphenyl, 7-(2, nitro, N-phenyl)-sulfonamidoquinoxaline

Functional Group	Frequency (cm ⁻¹)
C=C (Aromatic stretch)	1505.86 (1475-1600)
S=O	1173.30 (1180-1140) 1345.36 (1370-1300)
NH ₂	3345.36 (3500-3300)
Mono sub. benzene	770.40 (790-770)
NO ₂	1505.86 (1515-1560)

Table 5: mass characterization of 2, 3-Diphenyl, 7-(2,nitro,N-phenyl)-sulfonamidoquinoxaline

S. no	m/z	Fragment ion responsible
1	483	M ⁺ (base peak)
2	344	-NH ₂ C ₆ H ₄ NO ₂
3	378	-Ph CN
4	289	-A
5	405	-Ph

3.2 Anti-inflammatory Screening

This pharmacological activity was performed after obtaining approval of Institutional Animal Ethical Committee.

Synthesized compounds were subjected to testing for anti-inflammatory activity in albino rats employing the carrageenan induced rat paw edema test using Plethysmometer (UGO Basile 7140). The compounds were injected orally to the wistar albino rats. Percentage reduction in the inflammation (i.e. reduction in the hind paw edema volume of the animals) at different time interval after administration of

carrageenan was recorded, and test compounds (25mg/kg body weight) were compared with that of the animals administered with carrageenan using the reference standard Diclofenac sodium (10mg/kg body weight).

Data are expressed as Mean Paw Volume \pm SEM and analyzed by One-Way ANOVA followed by Dunnett's Test to determine the significance of the difference between the control group and group treated with test compounds. All the statistical calculations were carried out using Graph Pad InStat 3 Statistical Software. The result for anti-inflammatory activity is given in Table No 6, 7,8,9,10,11.

- L1 = 2, 3-Diphenyl, 7-sulfonamido quinoxaline
- L2 = 2,3-Diphenyl,7-(N phenyl)-sulfonamidoquinoxaline
- L3 = 2,3-Diphenyl,7-(N-acetyl)-sulfonamido quinoxaline
- Standard = Diclofenac sodium

Table 6: Mean paw volume and % inhibition of compounds after 30 min.

Compounds	Mean Paw Volume (ml) \pm SEM	% Inhibition of Edema
Control	1.23 \pm 0.022	---
L1	0.93 \pm 0.016**	61.03
L2	1.04 \pm 0.033*	13.04
L3	1.08 \pm 0.043**	20.06
Diclofenac sodium	0.97 \pm 0.033**	6.89

Test compounds = 25 mg/kg

Reference Standard, Diclofenac Sodium = 10 mg/kg

Mean \pm SEM [**p<0.01], [*p<0.05],

Statistical analysis was done by One-Way ANOVA followed by Dunnett's test.

Table 7: Mean paw volume and % inhibition of compounds after 1hr.

Compounds	Mean Paw Volume (ml) \pm SEM	% Inhibition of Edema
Control	0.99 \pm 0.040
L1	0.96 \pm 0.058	4.04
L2	0.96 \pm 0.052	3.82
L3	0.98 \pm 0.021	1.17
Diclofenac sodium	0.85 \pm 0.0085	15.15

Test compounds = 25 mg/kg

Reference Standard, Diclofenac Sodium = 10 mg/kg

Mean \pm SEM [**p<0.01], [*p<0.05],

Statistical analysis was done by One-Way ANOVA followed by Dunnett's test.

Table 8: Mean paw volume and % inhibition of compounds after 2 hr.

Compounds	Mean Paw Volume (ml) \pm SEM	% Inhibition of Edema
Control	1.23 \pm 0.022
L1	0.86 \pm 0.068	10.86
L2	0.96 \pm 0.062	7.84
L3	0.88 \pm 0.028	5.66
Diclofenac sodium	0.87 \pm 0.0089	16.06

Test compounds = 25 mg/kg

Reference Standard, Diclofenac Sodium = 10 mg/kg

Mean \pm SEM [$**p < 0.01$], [$*p < 0.05$],

Statistical analysis was done by One-Way ANOVA followed by Dunnett's test.

Table 9 :Mean paw volume and % inhibition of compounds after 3 hr.

Compounds	Mean Paw Volume (ml) \pm SEM	% Inhibition of Edema
Control	0.97 \pm 0.042
L1	0.95 \pm 0.059	12.77
L2	0.86 \pm 0.058	8.66
L3	0.98 \pm 0.041	9.90
Diclofenac sodium	0.85 \pm 0.0095	21.5

Test compounds = 25 mg/kg

Reference Standard, Diclofenac Sodium = 10 mg/kg

Mean \pm SEM [$**p < 0.01$], [$*p < 0.05$],

Statistical analysis was done by One-Way ANOVA followed by Dunnett's test.

Table 10:Mean paw volume and % inhibition of compounds after 6 hr.

Compounds	Mean Paw Volume (ml) \pm SEM	% Inhibition of Edema
Control	0.87 \pm 0.052
L1	0.85 \pm 0.058	19.15
L2	0.89 \pm 0.057	8.16
L3	0.99 \pm 0.046	17.90
Diclofenac sodium	0.89 \pm 0.0098	22.95

Test compounds = 25 mg/kg

Reference Standard, Diclofenac Sodium = 10 mg/kg

Mean \pm SEM [$**p < 0.01$], [$*p < 0.05$],

Statistical analysis was done by One-Way ANOVA followed by Dunnett's test.

Table 11:Mean paw volume and % inhibition of compounds after 24 hr.

Compounds	Mean Paw Volume (ml) \pm SEM	% Inhibition of Edema
Control	0.97 \pm 0.042
L1	0.75 \pm 0.068	19.98
L2	0.88 \pm 0.087	10.75
L3	0.89 \pm 0.066	19.07
Diclofenac sodium	0.79 \pm 0.0078	21.21

Test compounds = 25 mg/kg

Reference Standard, Diclofenac Sodium = 10 mg/kg

Mean \pm SEM [$**p < 0.01$], [$*p < 0.05$],

Statistical analysis was done by One-Way ANOVA followed by Dunnett's test.

4. Conclusion

The plan of work of present study was synthesis of sulfonamides derivatives of quinoxaline and physicochemical and spectral characterization, *in vitro* anti-inflammatory screening. All sulfonamides derivatives of quinoxaline were synthesized on the basis of elimination-addition mechanism.

The reaction was carried out in the presence of base, (pyridine) was used, all the reaction was refluxed with pyridine on water bath. The reaction time required for each reaction was different it was depends on the amines used. After completion of reaction, reaction mixture was poured into cold water and continuously stirred until product crystallized. All the sulfonamides derivatives were confirmed by TLC, IR, MS and ¹HNMR. The spectral characterization revealed the formation of sulfonamide derivatives.

Quinoxalin derivatives L1, L2, L3 were screened for in vitro anti-inflammatory activity in albino rat. All derivatives possess anti-inflammatory activity with percent inhibition ranging from 2.25% to 22.95%.

Acknowledgement:

Author is thankful to respected Dr. R. P. Marathe who guided me in M.Pharm Thesis. I am thankful to Dr. Mourya, Principal of Government College of Pharmacy, Aurangabad. Last but not the least we are thankful to Family and Friends for their moral support.

5. References

1. S. Ganapaty *et al*, Sar Study: Impact Of Hydrazide Hydrazones and Sulfonamide Side Chain On In Vitro Antimicrobial Activity Of Quinoxaline,” *Int.J. Pharmacol.Biol.* 2 (2) ,2008 , 13-18
2. Asuncion Burguete *et al*, “synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxaline-2-yl)-2-propen-1-one derivative,” *Bioorganic and Medicinal Chemistry Letters* 17 (2007) 6439-6443
3. E. Vicente, *et al*, “Synthesis and structure –activity relationship of 3-furyl and 3-thienylquinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives against Plasmodium falciparum,” <http://www.usc.es/congresos/ecsoc/11/ECSOC11.htm>&<http://www.mdpi.org/ecsoc-1>
4. Sandra Piraset *et al*, “Quinoxaline Chemistry ,Synthesis of Methyl [4-(Substituted 2-quinoxalinyloxy) Phenyl] acetate and evaluation of anticancer activity, *IL FARMACO* 59 (2004) 185-194
5. Agrawal, O.P. *Organic Chemistry Reactions and Reagents*, Goel publishing house, New Delhi, 627-628, 686-715
6. R.R.Gupta, M.Kumar , V.Gupta, *Heterocyclic Chemistry vol.1* Springer Publication , Pg.no.13-47
7. 16. Chatwal, G.R.; Anand, S.K.; *Instrumental Methods of Chemical Analysis*, Himalaya Publications, 2.599.
8. Arthur T. Vogel, *Elementary Practical Organic Chemistry Part 2, Qualitative Organic Analysis*, 2nd Edition, pg.no.-37,39,57,59,67.
9. Flavia Varano *et al.*, “Synthesis Of a Set of Ethyl 1-Carbamoyl-3-Oxoquinoxaline-2-Carboxylate And Of Their Constrained Analogues As Glycine / NMDA Receptor Antagonist” *Eur. J. Med. Chem.* 36(2001) 203-209
10. Vogel’s *Textbook of Practical Organic Chemistry*, 5th edition, International student edition, 1192.
11. Jerry March, *Advanced Organic Chemistry*, 4th edition, Wiley Publication pg. no 496-497
12. Sanyal S.N., *Reactions, Rearrangements and Reagents*, 4th edition 2003, Bharti Bhavan Publishers, pp.141-142.
13. B.S. Furniss. /A. J. Hanford. P.W.G. Smith/ A.R. Tatchell, *Vogel’s Text Book of Practical Organic Chemistry*, 5th Edition, pg.no.-127
14. Antonio Carta *et al.*, “Novel Synthesis Of Quinoxaline 1, 4 Dioxide With In Vitro Antimicrobial And Anticandida Activity,” *Eur. J. Medicinal chemistry* 37 (2002) 355-366.
15. Paolo Sanna, *et al*, “Synthesis Of 3, 6, 7- Substituted Quinoxaline -2 -Ones for Evaluation Of Antimicrobial And Anticancer Activity “*IL Farmaco* 54 (1999) 161-168, Elsevier.
16. Quinoxaline and related compound with antifungal activity, *J. Heterocyclic chemistry* 23-1391-1394.
